Try our beta test site
529 studies found for:    Open Studies | lymphoma OR CLL | Phase 1
Show Display Options
Rank Status Study
1 Recruiting A Phase I Study of AC0010 in Patients With Relapsed or Refractory CLL/SLL, MCL(Mantle Cell Lymphoma), DLBCL and Other Non-Hodgkin B-Cell Lymphoma
Condition: B-cell Lymphoma
Intervention: Drug: AC0010MA
2 Recruiting Study of ME-401 in Subjects With Relapsed/Refractory CLL/SLL or FL
Conditions: Chronic Lymphocytic Leukemia (CLL);   Small Lymphocytic Lymphoma;   Follicular Lymphoma
Intervention: Drug: ME-401
3 Recruiting Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas
Conditions: Chronic Lymphocytic Leukemia;   B-Cell Lymphoma
Interventions: Drug: DTRMWXHS-12;   Drug: DTRM-505;   Drug: DTRM-555
4 Recruiting Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Intervention: Drug: dimethyl fumarate
5 Recruiting Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma
Conditions: Chronic Lymphocytic Leukaemia (CLL);   B-Cell Non-Hodgkin Lymphoma (NHL);   Multiple Myeloma (MM)
Intervention: Drug: S 55746
6 Recruiting A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL
Conditions: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma;   Mantle Cell Lymphoma
Interventions: Drug: TGR-1202;   Drug: Ibrutinib
7 Recruiting A Safety and Pharmacokinetic Study of BTCT4465A, With or Without Single-dose Obinutuzumab Pretreatment, in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Conditions: Lymphocytic Leukemia, Chronic;   Lymphoma, Non Hodgkin
Interventions: Drug: BTCT4465A;   Drug: Obinutuzumab
8 Recruiting Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL
Conditions: Lymphoma;   Myeloma;   Leukemia
Intervention: Biological: Kappa CD28 T cells
9 Recruiting Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
Conditions: Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Acute Lymphocytic Leukemia
Interventions: Biological: CD19 CAR T Cells;   Drug: Fludarabine;   Drug: Cyclophosphamide
10 Recruiting Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL
Conditions: Non-hodgkin's Lymphoma;   Follicular Lymphoma;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Intervention: Drug: IMMU-114
11 Not yet recruiting Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLL
Conditions: Leukemia;   Lymphoma
Intervention: Biological: Anti-CD19-CAR
12 Not yet recruiting Immunotherapy With CD19 CAR γδT-cells for B-Cell Lymphoma, ALL and CLL
Conditions: Leukemia;   Lymphoma
Intervention: Biological: Anti-CD19-CAR γδT
13 Recruiting Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphomas
Conditions: Chronic Lymphocytic Leukemia;   B-cell Lymphomas
Intervention: Drug: DTRMWXHS-12
14 Recruiting PK, PD, Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Non-Hodgkin's B-Cell Lymphoma and B-Cell Chronic Lymphocytic Leukemia
Conditions: Non-Hodgkin's B-cell Lymphoma;   Leukemia, Lymphocytic, Chronic, B-Cell;   Small Lymphocytic Leukemia
Intervention: Drug: MT-3724
15 Not yet recruiting Study Evaluating the Efficacy and Safety With CAR-T Immunotherapy for CD19 Positive Lymphoma
Condition: Lymphoma
Intervention: Biological: The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T)
16 Recruiting Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas
Condition: B-cell Lymphoma
Intervention: Drug: Ibrutinib and immunochemotherapies
17 Recruiting Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: B-Cell Prolymphocytic Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Small Lymphocytic Lymphoma
Interventions: Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Other: Pharmacological Study
18 Not yet recruiting CD19-redirected Autologous Cells (CAR-CD19 T Cells)
Condition: CD19 Positive Malignant B-cell Leukemia and Lymphoma
Interventions: Genetic: CAR-CD19 T cells;   Drug: Fludarabine;   Drug: Cyclophosphamide
19 Recruiting A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas
Condition: B-Cell Lymphoma
Intervention: Drug: CPI-1205
20 Recruiting A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP
Condition: B-cell Lymphoma
Interventions: Drug: selinexor;   Drug: Rituximab;   Drug: Dexamethasone;   Drug: Oxaliplatin;   Drug: Cisplatin;   Drug: Cytarabine;   Drug: Gemcitabine

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.